Dachaigh › Aillse colorectal › Colorado › Denver
Sgrùdaidhean clionaigeach Aillse colorectal ann an Denver, CO
Tha 23 sgrùdaidhean airson Aillse colorectal a’ lorg phàirtichean aig làraichean ann agus timcheall air Denver (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
The Vanguard Study: Testing a New Way to Screen for Cancer
A’ fastadhFàilte do shaor-thoilich fhallain
- Kaiser Permanente-Franklin, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A’ fastadhÌre 1/2
- Rocky Mountain Cancer Center, Denver
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- AdventHealth Porter, Denver
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A’ fastadhÌre 3
- Intermountain Health Cancer Center Saint Joseph, Denver
- Intermountain Health Saint Joseph Hospital - Research Office, Denver
- Intermountain Health Saint Joseph Hospital, Denver
- agus 3 a bharrachd
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
A’ fastadhÌre 1/2
- Sarah Cannon Research Institute (SCRI), Denver
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
A’ fastadhÌre 3
- Rocky Mountain Cancer Centers, Denver
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A’ fastadhÌre 3
- Rocky Mountain Cancer Centers, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
A’ fastadhÌre 1/2
- SCRI at HCA Health One, Denver
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
A’ fastadhÌre 1
- SCRI Denver, Denver
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
A’ fastadhÌre 1
- Sarah Cannon Research Institute at HealthOne, Denver
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
A’ fastadhÌre 1
- Sarah Cannon Research Institute, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
A’ fastadhÌre 1
- Sarah Cannon Research Institue At Healthone, Denver
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
A’ fastadhÌre 3
- Rocky Mountain Cancer Centers, LLP, Denver
- Rocky Mountain Cancer Centers, LLP, Denver
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
A’ fastadhÌre 1
- Sarah Cannon Research Institute at HealthONE, Denver
CT-95 in Advanced Cancers Associated With Mesothelin Expression
A’ fastadhÌre 1
- Context Investigational Site, Denver
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
A’ fastadhÌre 2
- Rocky Mountain Cancer Center - Primary, Denver
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
A’ fastadhÌre 1
- Sarah Cannon Research Institute at HealthONE, Denver
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
A’ fastadhÌre 1/2
- SCRI - Denver, Denver
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital, Denver
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
A’ fastadhÌre 1
- Sarah Cannon Cancer Institute at HealthONE, Denver
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
A’ fastadhSgrùdadh amharc
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- agus 1 a bharrachd
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Sarah Cannon Research Institute at HealthONE, Denver
Sgrùdaidhean Aillse colorectal ann am bailtean eile
- Houston, TX102 sgrùdaidhean
- New York City, NY78 sgrùdaidhean
- Nashville, TN69 sgrùdaidhean
- Boston, MA63 sgrùdaidhean
- Los Angeles, CA59 sgrùdaidhean
- Arlington, VA52 sgrùdaidhean
- St. Louis, MO50 sgrùdaidhean
- San Antonio, TX46 sgrùdaidhean
- Philadelphia, PA44 sgrùdaidhean
- Grand Rapids, MI40 sgrùdaidhean
- Baldwin Park, CA37 sgrùdaidhean
- Chicago, IL34 sgrùdaidhean
Sgrùdaidhean eile ann an Denver
- Ailse metastatach29 sgrùdaidhean
- Aillse a' bhroilleach29 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag27 sgrùdaidhean
- Myeloma iomaill27 sgrùdaidhean
- Melanoma19 sgrùdaidhean
- Aillse Prostata19 sgrùdaidhean
- Aillse (gach seòrsa)18 sgrùdaidhean
- Cancer Ovarian16 sgrùdaidhean
- Ailseachadh nan Sgamhan16 sgrùdaidhean
- Ailse Endometrial15 sgrùdaidhean
- Liomfoma Neo-Hodgkin14 sgrùdaidhean
- Cancer Pancreatic13 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.